Date Title & Summary Additional Formats
August 6, 2024
Certara Reports Second Quarter 2024 Financial Results
Reiterates Full Year 2024 Financial Guidance RADNOR, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the second quarter of fiscal year 2024.
July 9, 2024
Certara to Acquire Chemaxon to Strengthen Drug Discovery Software Portfolio
Combined organization brings broader predictive capabilities to drug discovery at scale Reiterates full year 2024 guidance RADNOR, Pa., July 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced it has signed a definitive
July 2, 2024
Certara to Report Second Quarter 2024 Financial Results on August 6th, 2024
RADNOR, Pa., July 02, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the second quarter of 2024 after the market close on Tuesday, August 6 th , 2024.
June 17, 2024
Certara Launches Next Generation CoAuthor™ Generative AI Regulatory Writing Software
AI-enabled solutions accelerate regulatory and medical writing processes, enhancing quality, transparency, and efficiencies RADNOR, Pa., June 17, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today unveiled its next-generation CoAuthor
May 29, 2024
Certara to Participate in the Jefferies Global Healthcare Conference
RADNOR, Pa., May 29, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in the Jefferies Global Healthcare Conference. Company management will present at 11:30AM ET on Wednesday, June 5 th , 2024.
May 21, 2024
Certara Appoints New Chief Human Resources Officer & General Counsel
RADNOR, Pa., May 21, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, has appointed Rona Anhalt as Chief Human Resources Officer and Daniel Corcoran as General Counsel. "Rona and Daniel are leaders in their fields.
May 7, 2024
Certara Reports First Quarter 2024 Financial Results
Reiterates Full Year 2024 Financial Guidance PRINCETON, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the first quarter of fiscal year 2024. First Quarter Highlights: Revenue was $96.7 million,
April 16, 2024
Certara Launches Cloud Platform to Further Unify its End-to-End Scientific Software Platform
PRINCETON, N.J., April 16, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of Certara Cloud, the unifying platform that integrates its many scientific software solutions.
April 9, 2024
Certara to Report First Quarter 2024 Financial Results on May 7th, 2024 and Participate in the BofA Securities Healthcare Conference
PRINCETON, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the first quarter of 2024 after the market close on Tuesday, May 7 th , 2024.
February 29, 2024
Certara Reports Fourth Quarter 2023 Financial Results
Provides Full Year 2024 Financial Guidance PRINCETON, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the fourth quarter of fiscal year 2023. Fourth Quarter Highlights: Revenue was $88.0 million,
Displaying 11 - 20 of 21